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Pharmacokinetics of mycophenolate mofetil in patients with The use of mycophenolate mofetil (MMF) as an immu-
end-stage renal failure. nosuppressant for renal transplantation has increased
Background. Mycophenolate mofetil (MMF) acts as a pro- following reports of a reduction in the incidence of acutedrug for the immunosuppressive drug mycophenolic acid
rejection [1–3]. MMF is an inhibitor of inosine mono-(MPA). It is rapidly converted to MPA following oral ingestion.
phosphate dehydrogenase, a key enzyme in the de novoMPA is metabolized to MPA glucuronide (MPAG), which is
renally excreted. This study examines the pharmacokinetics of pathway of purine synthesis, which is particularly impor-
MPA and MPAG in patients with end-stage renal failure who tant for the proliferation of both T and B lymphocytes.
were on hemodialysis (N 5 10) or peritoneal dialysis (N 5 10) The ester prodrug MMF is rapidly converted in vivo totreatment.
the active drug mycophenolic acid (MPA), the parentMethods. After an overnight fast, a single oral dose of 1 g
compound having a half-life of less than two minutesMMF was given. Plasma concentrations of MPA and MPAG
were measured from 0 (predose) to 36 hours after administra- when given intravenously. MPA is, itself, metabolized
tion, using high-performance liquid chromatography (HPLC). to the phenolic glucuronide (MPAG), which is mostly
The area under the concentration time curve (AUC) from 0
eliminated in the urine, with small amounts present into 36 hours was calculated using the trapezoidal rule.
feces. A small rise in the MPA plasma concentration isResults. Mean (6 SD) AUC for MPA was 55.7 6 32.6 mg/L · h
for hemodialysis patients and 44.7 6 14.7 mg/L · h for peritoneal usually seen at 8 to 10 hours after administration because
dialysis patients, which is similar to expected values for subjects of enterohepatic recirculation. MPAG is thought to have
with normal renal function. The mean (6 SD) maximum no pharmacological activity but may be responsible for
plasma concentration (Cmax) for MPA was lower than would some side effects [4]. Recently, a second metabolite ofbe expected for subjects with normal renal function (16.01 6
MPA, the acyl glucuronide, has been described, which10.61 mg/L for hemodialysis, 11.48 6 4.98 mg/L for peritoneal
dialysis). MPAG clearance was prolonged with AUC approxi- like the parent compound does inhibit inosine mono-
mately five times what would be expected in subjects with phosphate dehydrogenase [5].
normal renal function (1565 6 596 mg/L · h for hemodialysis, During a study using MMF in an attempt to reduce
1386 6 410 mg/L · h for peritoneal dialysis). There was no
circulating levels of antibodies to human leukocyte anti-significant difference for any of the pharmacokinetic parame-
gens, in dialysis patients on the transplant waiting list,ters between subjects on hemodialysis and those on peritoneal
dialysis. Plasma concentrations of MPA and MPAG did not we were unable to reach the intended target dose of 2 g
fall significantly during hemodialysis. No MPA was detectable daily in any patient because of gastrointestinal intoler-
in hemodialysis or peritoneal dialysis fluid, but small amounts ance. The pharmacokinetics of MMF have been defined
of MPAG were detected in hemodialysis fluid in 1 out of 10
largely in subjects with normal renal function, with rela-subjects and in peritoneal dialysis fluid in 3 out of 10 subjects.
tively little information available for patients with end-Conclusions. The accumulation of MPAG may be responsi-
ble for the poor gastrointestinal tolerance of this drug in dialysis stage renal failure [6–8]. This is clearly an important issue
patients and probably limits the maximum dose of MMF that for a drug used in patients with nonfunctioning renal trans-
can be tolerated. plants and increasingly in patients with immunologically
mediated renal diseases. The paucity of data on the han-
dling of MMF in patients with established end-stage renalKey words: renal failure, dialysate, immunosuppression, peritoneal di-
alysis, hemodialysis. failure on treatment by dialysis makes it difficult to
choose a rational dosing schedule for these patients.Received for publication May 12, 1999
In the current study, the pharmacokinetics of MMFand in revised form September 2, 1999
Accepted for publication October 12, 1999 following a single oral dose of 1 g were studied in patients
with end-stage renal failure on treatment by dialysis.Ó 2000 by the International Society of Nephrology
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Table 1. Demographic data on the first day of the study, but were dialyzed on the
second day, when an extra blood sample was collectedPeritoneal
Hemodialysis dialysis immediately after dialysis. Samples of PD fluid were
Age years 48 (28–79) 51.5 (34–78) collected 24 hours after taking MMF, and samples of
Sex male/female 8/2 7/3 HD fluid were collected for analysis. A single patient on
Height m 1.63 (1.22–1.83) 1.66 (1.55–1.80)
APD was treated with a regular oral dose of 750 mgWeight kg 63.5 (45–91) 70.5 (52.5–92)
Hemoglobin concentration g/dL 9.3 (8.2–12.2) 10.2 (8.3–12.5) MMF daily (250 mg in the morning and 500 mg in the
Serum albumin g/L 42.5 (30–48) 38 (32–44) evening) for four weeks following the initial 36-hour
Kt/Va 1.48 (1.27–1.9) 2.65 (1.85–3.16)
study, and an abbreviated series of samples (predoseRace Caucasian/African/Asian 2/6/2 4/3/3
and 20, 40, 75, and 120 min after dosing) was collectedValues shown are median (range) unless otherwise stated.
aKt/V is a measure of urea clearance on dialysis related to the patient’s calcu- following an oral dose of 250 mg taken at 8 a.m.
lated total body water and is an indicator of the delivered dialysis dose
Assay of mycophenolic acid and mycophenolic
acid glucuronide
Mycophenolic acid and MPAG concentrations wereMETHODS
measured using a Good Laboratory Practice validated
Patients high-performance liquid chromatographic (HPLC)
The patients invited to volunteer for participation in method. Briefly, 100 mL of plasma were extracted using
the study were aged over 18 years and were being treated a C2 Isolute cartridge, and 100 mL of the reconstituted
for end-stage renal failure at St. George’s Hospital: 10 extract were injected into the HPLC column (Zorbax
by hemodialysis (HD) and 10 by peritoneal dialysis [PD; Rx-C8, 5 mm, 15 cm). The internal standard for MPA
8 continuous ambulatory PD (CAPD) and 2 nocturnal was RS-60461 (Roche, Palo Alto, CA, USA) and for
automated PD (APD)]. The demographic characteristics MPAG was mycophenolate phenolphtaleine glucuro-
of the patients are shown in Table 1. Cellulose (Haemo- nide (Sigma, St. Louis, MO, USA). Calibrators were
phane, Hospal, Rugby, UK) dialysis membranes were prepared by spiking human plasma with stock solutions
used for all patients on HD. Kt/V (a measure of urea to reach a final concentration in the range 1 to 50 mg/L
clearance by dialysis related to the patient’s calculated for MPA and 25 to 1000 mg/L for MPAG. Detection
total body water) was recorded as an estimate of the was by means of ultraviolet spectrophotometry at 305 nm.
delivered dialysis dose. A single pool urea kinetic model The lower limits of quantitation for MPA and MPAG
was used to calculate Kt/V for each session for HD, and were 0.5 and 5 mg/L, respectively. Within and between-
Kt/V per week for PD was calculated using Adequeste assay reproducibility (CV%) for MPA were 4.5 and 9%,
software (Baxter, Columbia, MD, USA). Residual renal respectively, at a concentration of 2.1 mg/L; comparable
function was estimated from 24-hour urine collections data for MPAG at a concentration of 20.5 mg/L were
and included in the calculations. The serum albumin 2.9 and 2.9%. MPA was purchased from Sigma Chemi-
concentration did not differ significantly between sub- cals, and MPAG was a gift from Hoffmann-la-Roche
jects on HD and PD (Mann–Whitney U test, P 5 0.08). (Nutley, NJ, USA).
Patients were excluded from the study if they were taking
any other immunosuppressive drugs, were pregnant Pharmacokinetic analysis
(confirmed by pregnancy testing using blood samples in The maximum plasma concentration (Cmax) and the
premenopausal women), were nursing mothers, had a time to maximum plasma concentration (tmax) were ob-
known malignant disease, or had clinical evidence of tained from the observed plasma concentration time pro-
infection. Subjects continued to take their other regular files. The area under the plasma concentration-time
prescribed medications, with the exception of antacids, curves (AUC) was calculated using the linear trapezoidal
which interfere with the absorption of MMF. method to the peak concentration and then the log-
trapezoidal method from the peak onward.Study design
The study design was approved by the local research Statistics
ethics committee, and all patients gave written informed Comparisons between the groups were made using
consent. Subjects were given a single oral dose of 1 g one-way analysis of variance (ANOVA).
MMF at 8 a.m. on the first day of the study. They were
fasted overnight and were not allowed to eat until two
RESULTShours after dosing. Blood samples (2 mL) were collected
into ethylenediaminetetraacetic acid (EDTA): predose The results were analyzed separately for patients on
HD and PD, with CAPD and APD being treated as aand 20, 40, 75 minutes, 2, 3, 4, 6, 8, 10, 12, 24, and 36
hours after dosing. Patients on HD were not dialyzed single group.
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Fig. 2. Plasma concentrations of mycophenolic acid glucuronide
(MPAG) following a single oral dose of 1 g of mycophenolate mofetil
Fig. 1. Plasma concentrations of myophenolic acid (MPA) following (MMF). The mean plasma concentration of MPAG following a single
a single oral dose of 1 g myophenolate mofetil (MMF). The mean oral dose of 1 g of MMF is shown for patients on treatment by HD
plasma concentration of MPA following a single oral dose of 1g of (d; N 5 10), CAPD (s; N 5 8), and APD (n; N 5 2).
MMF is shown for patients on treatment by HD (d; N 5 10), CAPD
(s; N 5 8), and APD (n; N 5 2).
MMF. Interestingly, immediately following renal trans-Plasma concentrations over time for each group for
plantation twice the dose of MMF is required to achieveMPA are shown in Figure 1 and for MPAG in Figure 2
the same drug exposure as 20 days later [9]. The reasonshowing rapid clearance of MPA but very slow clearance
for the lower Cmax is unclear, but it has been speculatedof MPAG.
that MMF is less well absorbed in the uremic state. TheThe pharmacokinetic parameters AUC, tmax, and Cmax
other pharmacokinetic parameters, AUC and rate ofare shown in Table 2. There was no significant difference
clearance, were found to be similar to those expected forin any of the parameters between patients treated by
subjects with normal renal function, confirming previousHD and PD.
observations [8, 10].There was no fall in MPA or MPAG levels following
The most striking observation was the slow clearanceHD. No MPA was found in either PD fluid or in HD fluid.
of MPAG in patients with end-stage renal failure. OurMPAG was detectable in PD fluid from three patients on
AUC calculations for MPAG are in close agreementCAPD at concentrations of 7.0, 9.0, and 12.0 mg/L and
with those found by Johnson et al for six HD patientsin dialysis fluid for a single patient on HD at a concentra-
[8], with clear evidence of accumulation in the singletion of 9.0 mg/L.
patient studied on a maintenance dose in our study. ItGiven the previously mentioned data, significant accu-
has also been noted in renal transplant recipients withmulation of MPAG would be expected with regular dos-
variable renal function that AUC for MPAG increaseding. We had the opportunity to confirm this in one patient
as glomerular filtration rate decreased [8]. The AUC foron APD who, subsequent to the pharmacokinetic study,
MPAG following a single dose was approximately fivewas commenced on regular MMF. After four weeks on
times higher than that found in subjects with normala dose of 250 mg in the morning and 500 mg in the
renal function [8, 10]. Zanker et al also found significantevening, a five-sample, two-hour profile for MPA and
accumulation of MPAG in patients with nonfunctioningMPAG plasma concentrations was taken. This confirmed
renal transplants given 3 g of MMF daily with troughsignificant accumulation of MPAG (Table 3).
levels as high as 358 mg/L [6]. The causative agent forNone of the subjects reported any side effects follow-
the gastrointestinal side effects has not been defineding the single drug dose.
clearly, but MPAG is a candidate. It remains to be estab-
lished what effect the accumulation of MPAG has on
DISCUSSION the handling of MPA, but it may displace protein-bound
MPA with an increase in the free concentration andThe Cmax of MPA in dialysis patients was lower than
altered pharmacodynamics. Methods for assay of freewould be expected for subjects with normal renal func-
MPA concentration remain to be properly established.tion. The mean Cmax in the current study was 11.48 mg/L
According to Nowak and Shaw, the temperature has afor patients on PD and 16.01 mg/L for HD patients, in
significant effect on the concentration of the free frac-close agreement with a value of 16.1 mg/L found for HD
tion, so currently published data can be flawed by assayspatients by Johnson et al [8]. In that study, Cmax was 25.3
mg/L for normal subjects following a single 1 g dose of being performed at 258C rather than 378C [11]. The con-
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Table 2. Pharmacokinetic parameters
MPA MPAG
Dialysis
modality AUC mg/L·ha Cmax mg/La tmax hb AUC mg/L·ha Cmax mg/La tmax hb
HD 55.7632.6 16.01610.61 0.66 (0.33–2.00) 15656596 76.26625.09 2.00 (1.25–3.00)
PD 44.7614.7 11.4864.98 0.66 (0.66–2.00) 13866410 71.55626.88 2.00 (1.25–4.00)
Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; MPA, mycophenolic acid; MPAG, mycophenolic acid glucuronide; AUC, area under the concentration-
time curve; Cmax, maximum plasma concentration; tmax, time to maximum plasma concentration.
aMean 6 standard deviation
bMedian (range)
Table 3. MPA and MPAG plasma concentrations side effects without parallel accumulation of the active
with regular dosing
drug makes dose selection difficult, as a dose reduction
Plasma concentration to avoid MPAG accumulation could potentially result
Plasma concentration after oral dose of 250 in subtherapeutic plasma concentrations of the activeafter a single oral dose mg with regular dose
drug MPA. High concentrations of MPAG may increaseof 1 g MMF of 750 mg MMF daily
the concentration of free MPA with increased efficacy,Time after dose MPA MPAG MPA MPAG
min mg/L mg/L mg/L mg/L and further work is required to determine whether this
occurs. The therapeutic plasma concentration of MPAPre-dose 0 0 2.8 120
20 0.59 0 2.8 113 in dialysis patients needs to be determined, and if this
40 2.95 0 5.1 122 cannot be achieved without excessive side effects, then75 2.36 12.7 5.1 133
it may not be possible to use MMF in this patient group.120 5.5 23.64 2.6 142
Clearly, these observations also have implications forAbbreviations are in Table 2. A single patient on APD was treated with a
regular oral dose of 750 mg MMF daily for 4 weeks following the initial 36 hour drug dosing in patients with acute renal failure. On bal-
study, and an abbreviated series of samples (pre-dose and 20, 40, 75 and 120
ance, based on these observations, when using MMF inminutes after dosing) was collected following an oral dose of 250 mg taken at
08:00. patients with end-stage renal failure on dialysis, we
would suggest using lower doses than in individuals with
normal renal function, in contrast to the advice given
elsewhere [6, 8]. It would probably be reasonable to startcentration-controlled trials determining efficacy of MMF
at a dose of 250 mg twice daily increasing to a dose ofin relationship to blood MPA concentrations measured
500 mg twice daily if the lower dose is tolerated. In usingtotal MPA with no measurement of free MPA [12]. Fur-
this regime, we have found predose plasma concentra-ther work is required to define factors altering the level
tions of MPA in the range of 2 to 4 mg/L and MPAGof protein binding of MPA and the pharmacological ef-
of 50 to 70 mg/L with regular dosing (data not shown).fects of increased free concentrations of MPA.
MMF should certainly be used with caution in theseAn intriguing difference between our data and pre-
patients. Although therapeutic drug monitoring has notviously published reports was the complete absence of
routinely been employed for monitoring the administra-clearance of MPA by HD and the clearance of MPAG
tion of MMF, measurement of predose plasma concen-in only 1 out of 10 subjects [6, 8]. In the present study,
trations of MPA and MPAG in patients with end-stagethe dose of dialysis delivered, as quantitated by Kt/V, was
renal failure would be prudent.adequate, with all patients exceeding the United Kingdom
Renal Association recommended target of 1.2 [13]. The
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